Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 8/20 | 0.73 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.62 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.61 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.61 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 2/20 | 0.56 |
| ▸ | PARP15 | Q460N3 | 5/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 3/20 | 0.49 |
| ▸ | PARP4 | Q9UKK3 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.48 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.48 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3636392 | 0.98 | PARP10 (0.71) | PARP10CHEK2SENP8SENP6MAP4K4 | |
| SCHEMBL3133910 | 0.90 | PARP10 (0.64) | PARP10CHEK2SENP8SENP6MAP4K4 | |
| Trifluoroacetic Acid SCHEMBL4629826 | 0.90 | PARP10 (0.60) | PARP10CHEK2SENP8SENP6MAP4K4 | |
| Trifluoroacetic Acid SCHEMBL6156463 | 0.90 | PARP10 (0.60) | PARP10CHEK2SENP8SENP6MAP4K4 | |
| Hydrochloric Acid SCHEMBL3127575 | 0.89 | PARP10 (0.62) | PARP10CHEK2SENP8SENP6MAP4K4 | |
| SCHEMBL4241025 | 0.85 | HRH1 (0.62) | PARP10CHEK2SENP8SENP6HRH1 | |
| SCHEMBL3028371 | 0.84 | PARP10 (0.93) | PARP10SENP8SENP6MAP4K4PARP15 | |
| SCHEMBL19852400 | 0.83 | HRH1 (0.56) | PARP10CHEK2SENP8SENP6MAP4K4 | |
| SCHEMBL10964232 | 0.83 | HRH1 (0.56) | PARP10CHEK2SENP8SENP6HRH1 | |
| SCHEMBL19381882 | 0.83 | PARP10 (0.90) | PARP10SENP8SENP6MAP4K4PARP15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062100-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| EP-4065570-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2022-10-05 | — | — | EP | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| WO-2021105115-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2021-06-03 | — | — | WO | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2018026371-A1 | DUAL NAV1.2/5HT2A INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-02-08 | — | — | WO | disclosed |
| EP-2607362-B1 | Piperidine and piperazine carboxylates as FAAH inhibitors | ASTELLAS PHARMA INC (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-1697307-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20100009972-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | ASTELLAS PHARMA INC. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FMC CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FMC CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2008-10-02 | — | — | US | disclosed |
| US-7384970-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2008-06-10 | — | — | US | disclosed |
| EP-1849773-A1 | PYRIDYL NON-AROMATIC NITROGENATED HETEROCYCLIC-1-CARBOXYLATE ESTER DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196100-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-03-27 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070010558-A1 | Opioid receptor antagonists | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | PARP10 2251/4885CHEK2 3578/4885SENP8 4166/4885 |
| US-20230062100-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | PARP10 863/4885CHEK2 395/4885SENP8 3079/4885 |
| US-20080306046-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Derivative | FAAH, FAAH2, APEH | PARP10 2633/4885CHEK2 4455/4885SENP8 2656/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | PARP10 2251/4885CHEK2 3578/4885SENP8 4166/4885 |
| US-20100009972-A1 | Pyridyl Non-Aromatic Nitrogen-Containing Heterocyclic-1-Carboxylate Compound | FAAH, FAAH2, CNR2 | PARP10 2115/4885CHEK2 3848/4885SENP8 1733/4885 |
| US-20080242671-A1 | INHIBITORS OF CATHEPSIN S | CTSS, CTSB, CTSZ | PARP10 2040/4885CHEK2 3713/4885SENP8 209/4885 |
| US-20070010558-A1 | Opioid receptor antagonists | OPRM1, OPRK1, OPRL1 | PARP10 3055/4885CHEK2 4880/4885SENP8 4314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.